XML 98 R57.htm IDEA: XBRL DOCUMENT
v3.19.3

License agreements - MacroGenics (Details) - USD ($) $ in Thousands | 1 Months Ended | 3 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Nov. 30, 2018 | Sep. 30, 2018 | Dec. 31, 2017 | Sep. 30, 2019 | Sep. 30, 2018 | Sep. 30, 2019 | Sep. 30, 2018 | Dec. 31, 2018
License agreements |  |  |  |  |  |  |  |
Research and development |  |  |  | $ 281,336 | $ 292,527 | $ 841,244 | $ 893,719 |
MacroGenics |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |
Upfront payment under license agreement |  |  | $ 150,000 |  |  |  |  |
Research and development | $ 5,000 | $ 10,000 |  | 14,100 | $ 6,300 | 33,300 | $ 23,700 |
MacroGenics | Accrued and other liabilities |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |
Accrued and other liabilities |  |  |  | $ 2,400 |  | $ 2,400 |  | $ 3,200
Minimum | MacroGenics |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  | 15.00% |  |  |  |  |
Maximum | MacroGenics |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |
Royalty payments on future global net sales (as a percent) |  |  | 24.00% |  |  |  |  |
Development and Regulatory Milestones | Maximum | MacroGenics |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  | $ 420,000 |  |  |  |  |
Commercialization Milestones | Minimum | MacroGenics |  |  |  |  |  |  |  |
License agreements |  |  |  |  |  |  |  |
Additional milestone payments under the license agreement |  |  | $ 330,000 |  |  |  |  |

X
- Definition Represents the additional milestone payments to be made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount of the upfront payment made under the license agreement. + References No definition available. + Details
Name: | incy_LicenseAgreementUpfrontPaymentAmountPaid
Namespace Prefix: | incy_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents range of tiered, double-digit royalty payments on future global sales if product is successfully commercialized. + References No definition available. + Details
Name: | incy_PercentageOfRoyaltyRatePayments
Namespace Prefix: | incy_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other. + References No definition available. + Details
Name: | us-gaap_AccruedLiabilitiesAndOtherLiabilities
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_RelatedPartyTransactionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 985 -SubTopic 20 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 730 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=incy_MacrogenicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | incy_AchievementOfMilestoneAxis=incy_CommercializationMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |